secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0001104659-25-056996
Event type: litigation
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance settles YUPELRI patent litigation with Eugia; generic launch set for 2039
--------------------------------------------------------------------------------

- Settlement resolves Hatch-Waxman litigation over YUPELRI (revefenacin) with Eugia (Aurobindo).
- Eugia granted royalty-free license to market generic version on or after April 23, 2039.
- Settlement subject to review by U.S. DOJ and FTC as required by law.
- Patent litigation continues against two other ANDA filers: Cipla and Mankind Pharma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925056996/0001104659-25-056996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925056996/tm2517353d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-056996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer